Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 peptide vaccine
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
NY-ESO-1 peptide vaccine is an investigational cancer immunotherapy developed by the National Cancer Institute (NCI). It targets the NY-ESO-1 antigen, a tumor-specific cancer-testis antigen expressed in various malignancies, including melanoma. The vaccine is composed of synthetic peptides, specifically the HLA-A*0201-restricted peptide (ESO-1:165V) and the HLA-DP4-restricted peptide (NY-ESO-1:161-180). These peptides are designed to stimulate CD8+ cytotoxic T-cell and CD4+ helper T-cell immune responses, respectively, against tumor cells expressing the NY-ESO-1 protein. It has been primarily evaluated in Phase II clinical trials for patients with refractory metastatic melanoma who are positive for the relevant HLA alleles.
- Other names
- NY-ESO-1 vaccineNY-ESO1 vaccineNY-ESO 1 vaccineNY-ESO-1 peptide immunotherapyNY-ESO1 peptide immunotherapyNY-ESO 1 peptide immunotherapy
02
Targets
NY-ESO-1 (New york esophageal squamous cell carcinoma 1)
Beyond the preview
Go deeper on NY-ESO-1 peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1 peptide vaccine.